Allergan received approval from the Food and Drug Administration (FDA) to market JUVÉDERM VOLBELLA®XC, for use in the lips for lip augmentation and for correction of perioral rhytids, commonly referred to as perioral lines. However, it was previously approved and has been used in Europe since 2011.
In clinical trials, JUVÉDERM VOLBELLA® XC was found to effectively increase lip fullness and soften the appearance of lines around the mouth in a majority of subjects through one year.
This filler is best for those who want a subtle enhancement and not a lot of volume. Just as with Voluma and Vollure, this product is formulated with VYCROSS®, a proprietary filler technology from Allergan, which yields smooth products that have been engineered to address specific patient concerns such as lip fullness, age-related volume loss in the cheek area, or perioral rhytids (lip lines). VYCROSS® blends different molecular weights of hyaluronic acid which contributes to the gel’s duration, with less water attraction. In addition, JUVÉDERM VOLBELLA® XC has been customized with a lower HA concentration (15 mg/mL), while still providing long-lasting results of about one year. This makes JUVÉDERM VOLBELLA® XC a soft, smooth gel appropriate for adding subtle volume to the lips and softening the appearance of perioral lines (lip lines).
Lasts 12 months
Is instantly reversible
FDA Approval – June 2016
Used in Europe – 2011